These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18593994)

  • 1. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
    de Haas T; Hasselt N; Troost D; Caron H; Popovic M; Zadravec-Zaletel L; Grajkowska W; Perek M; Osterheld MC; Ellison D; Baas F; Versteeg R; Kool M
    Clin Cancer Res; 2008 Jul; 14(13):4154-60. PubMed ID: 18593994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
    Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
    Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
    Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
    Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicobiological model predicting survival in medulloblastoma.
    Ray A; Ho M; Ma J; Parkes RK; Mainprize TG; Ueda S; McLaughlin J; Bouffet E; Rutka JT; Hawkins CE
    Clin Cancer Res; 2004 Nov; 10(22):7613-20. PubMed ID: 15569993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression.
    Moriuchi S; Shimizu K; Miyao Y; Hayakawa T
    Anticancer Res; 1996; 16(5A):2687-92. PubMed ID: 8917371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
    Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
    Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
    Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
    J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk stratification in medulloblastoma: screening for molecular markers].
    Ebinger M; Senf L; Scheurlen W
    Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
    Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
    Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
    Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
    J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
    Pizer BL; Clifford SC
    Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular parameters for risk stratification in Mexican children with medulloblastoma.
    López-Aguilar E; Sepúlveda-Vildósola AC; Rivera-Márquez H; Siordia-Reyes G; Betanzos-Cabrera Y; Cerecedo-Díaz F; del Angel VW; Diegopérez-Ramírez J
    Arch Med Res; 2007 Oct; 38(7):769-73. PubMed ID: 17845897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological and molecular heterogeneity of medulloblastoma.
    Gulino A; Arcella A; Giangaspero F
    Curr Opin Oncol; 2008 Nov; 20(6):668-75. PubMed ID: 18841049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival.
    Zitterbart K; Zavrelova I; Kadlecova J; Spesna R; Kratochvilova A; Pavelka Z; Sterba J
    Acta Neuropathol; 2007 Dec; 114(6):641-50. PubMed ID: 17912537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
    Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
    Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion.
    Marchetti D; Mrak RE; Paulsen DD; Sinnappah-Kang ND
    J Exp Clin Cancer Res; 2007 Mar; 26(1):5-23. PubMed ID: 17550129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of stathmin protein predicts a fulminant course in medulloblastoma.
    Kuo MF; Wang HS; Kuo QT; Shun CT; Hsu HC; Yang SH; Yuan RH
    J Neurosurg Pediatr; 2009 Jul; 4(1):74-80. PubMed ID: 19569914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.